Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02213107 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02213107 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 43 participants.
The verdict
NCT02213107, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Determine the effect of enzalutamide and dutasteride or finasteride on the time to prostatic-specific antigen level increase in patients age 65 or older.
Interventions
- DRUG Enzalutamide and Dutasteride or finasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-09 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02213107
The ClinicalTrials.gov registry entry for NCT02213107 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enzalutamide and Dutasteride or finasteride is the first listed.
NCT02213107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02213107 about?
NCT02213107 is a clinical study titled "Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.". Determine the effect of enzalutamide and dutasteride or finasteride on the time to prostatic-specific antigen level increase in patients age 65 or older.
What is the current status of trial NCT02213107?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2014-09. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT02213107?
The interventions under investigation include: Enzalutamide and Dutasteride or finasteride (DRUG).
Who is sponsoring clinical trial NCT02213107?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.